Zubsolv

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Buprenorphine hydrochloride, Naloxone hydrochloride dihydrate

Available from:

Accord Healthcare S.L.U.

ATC code:

N07BC51

INN (International Name):

buprenorphine, naloxone

Therapeutic group:

Drogi oħra tas-sistema nervuża

Therapeutic area:

Disturbi Relatati ma 'Opjojdi

Therapeutic indications:

Trattament ta 'sostituzzjoni għal dipendenza fuq id-droga opioid, fi ħdan qafas ta' trattament mediku, soċjali u psikoloġiku. L-intenzjoni tal-komponent ta 'naloxone hija li tiskoraġġixxi l-użu ħażin minn ġol-vina. Il-kura hija maħsuba għall-użu f'adulti u adolexxenti ta 'aktar minn 15-il sena li qablu li jiġu ttrattati għall-vizzju.

Product summary:

Revision: 10

Authorization status:

Awtorizzat

Authorization date:

2017-11-10

Patient Information leaflet

                                43
B. FULJETT TA’ TAGĦRIF
44
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-PAZJENT
ZUBSOLV 0.7 MG/0.18 MG PILLOLI GĦAL TAĦT L-ILSIEN
ZUBSOLV 1.4 MG/0.36 MG PILLOLI GĦAL TAĦT L-ILSIEN
ZUBSOLV 2.9MG/0.71 MG PILLOLI GĦAL TAĦT L-ILSIEN
ZUBSOLV 5.7 MG/1.4 MG PILLOLI GĦAL TAĦT L-ILSIEN
ZUBSOLV 8.6 MG/2.1 MG PILLOLI GĦAL TAĦT L-ILSIEN
ZUBSOLV 11.4 MG/2.9MG PILLOLI GĦAL TAĦT L-ILSIEN
buprenorphine/naloxone
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anke jekk għandhom l-istess sinjali ta’
mard bħal tiegħek.
-
Jekk ikollok xi effett sekondarju, kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi
effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Zubsolv u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Zubsolv
3.
Kif tieħu Zubsolv
4.
Effetti sekondarji possibbli
5.
Kif taħżen Zubsolv
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU ZUBSOLV U GĦALXIEX JINTUŻA
Zubsolv fiha is-sustanzi attivi buprenorphine u naloxone. Zubsolv
jintuża għat-trattament ta’
dipendenza fuq mediċini opjojdi (narkotiċi) bħall-eroina jew
morfina fl-persuni bill-vizzju tad-doga li
jkunu qablu li jiġu ttrattati għall-vizzju tagħhom. Zubsolv
jintuża fl-adulti u l-adolexxenti li jkollhom
aktar minn 15-il sena, li jkun qed jirċievu wkoll sapport mediku,
soċjali u psikoloġiku.
KIF JAĦDEM ZUBSOLV
Il-pillola fiha buprenorphine, li hu responsabbli għat-trattament
ta’ dipendenza fuq l-opjojdi
(narkotiċi). Fih ukoll naloxone li jintuża biex jiskoraġġixxi
abbuż tal-għoti ġol-vini tal-prodott.
2.
X’GĦANDEK TKUN TAF QABEL MA TIEĦU ZUBSOLV
TIĦUX ZUBSOLV
jekk inti:
-
allerġiku għal b
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Zubsolv 0.7 mg/0.18 mg pilloli għal taħt l-ilsien
Zubsolv 1.4 mg/0.36 mg pilloli għal taħt l-ilsien
Zubsolv 2.9 mg/0.71 mg pilloli għal taħt l-ilsien
Zubsolv 5.7 mg/1.4 mg pilloli għal taħt l-ilsien
Zubsolv 8.6 mg/2.1 mg pilloli għal taħt l-ilsien
Zubsolv 11.4 mg/2.9 mg pilloli għal taħt l-ilsien
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Zubsolv 0.7 mg/0.18 mg pilloli għal taħt l-ilsien
Kull pillola għal taħt l-ilsien ta’ 0.7 mg/0.18 mg fiha 0.7 mg
ta’ buprenorphine (bħala hydrochloride) u
0.18 mg ta’ naloxone (bħala hydrochloride dihydrate).
Zubsolv 1.4 mg/0.36 mg pilloli għal taħt l-ilsien
Kull pillola għal taħt l-ilsien ta’ 1.4 mg/0.36 mg fiha 1.4 mg
ta’ buprenorphine (bħala hydrochloride) u
0.36 mg ta’ naloxone (bħala hydrochloride dihydrate).
Zubsolv 2.9 mg/0.71 mg pilloli għal taħt l-ilsien
Kull pillola għal taħt l-ilsien ta’ 2.9 mg/0.71 mg fiha 2.9 mg
ta’ buprenorphine (bħala hydrochloride) u
0.71 mg ta’ naloxone (bħala hydrochloride dihydrate).
Zubsolv 5.7 mg/1.4 mg pilloli għal taħ t l-ilsien
Kull pillola għal taħt l-ilsien ta’ 5.7 mg/1.4 mg fiha 5.7 mg
ta’ buprenorphine (bħala hydrochloride) u
1.4 mg ta’ naloxone (bħala hydrochloride dihydrate).
Zubsolv 8.6 mg/2.1 mg pilloli għal taħ t l-ilsien
Kull pillola għal taħt l-ilsien ta’ 8.6 mg/2.1 mg fiha 8.6 mg
ta’ buprenorphine (bħala hydrochloride) u
2.1 mg ta’ naloxone (bħala hydrochloride dihydrate).
Zubsolv 11.4 mg/2.9 mg pilloli għal taħ t l-ilsien
Kull pillola għal taħt l-ilsien ta’ 11.4 mg/2.9 mg fiha 11.4 mg
ta’ buprenorphine (bħala hydrochloride)
u
2.9 mg ta’ naloxone (bħala hydrochloride dihydrate).
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola għal taħt l-ilsien
Zubsolv 0.7 mg/0.18 mg pilloli għal taħt l-ilsien
Pillola bajda għal bajda tagħti fl-isfar, ovali, b’tul ta’ 6.8
mm u wisa’ ta’ 4.0 mm, imnaqqxa b’“.7” fuq
naħ
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 10-10-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 10-10-2023
Public Assessment Report Public Assessment Report Bulgarian 12-01-2018
Patient Information leaflet Patient Information leaflet Spanish 10-10-2023
Public Assessment Report Public Assessment Report Spanish 12-01-2018
Patient Information leaflet Patient Information leaflet Czech 10-10-2023
Public Assessment Report Public Assessment Report Czech 12-01-2018
Patient Information leaflet Patient Information leaflet Danish 10-10-2023
Public Assessment Report Public Assessment Report Danish 12-01-2018
Patient Information leaflet Patient Information leaflet German 10-10-2023
Public Assessment Report Public Assessment Report German 12-01-2018
Patient Information leaflet Patient Information leaflet Estonian 10-10-2023
Public Assessment Report Public Assessment Report Estonian 12-01-2018
Patient Information leaflet Patient Information leaflet Greek 10-10-2023
Public Assessment Report Public Assessment Report Greek 12-01-2018
Patient Information leaflet Patient Information leaflet English 10-10-2023
Public Assessment Report Public Assessment Report English 12-01-2018
Patient Information leaflet Patient Information leaflet French 10-10-2023
Public Assessment Report Public Assessment Report French 12-01-2018
Patient Information leaflet Patient Information leaflet Italian 10-10-2023
Public Assessment Report Public Assessment Report Italian 12-01-2018
Patient Information leaflet Patient Information leaflet Latvian 10-10-2023
Public Assessment Report Public Assessment Report Latvian 12-01-2018
Patient Information leaflet Patient Information leaflet Lithuanian 10-10-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 10-10-2023
Public Assessment Report Public Assessment Report Lithuanian 12-01-2018
Patient Information leaflet Patient Information leaflet Hungarian 10-10-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 10-10-2023
Public Assessment Report Public Assessment Report Hungarian 12-01-2018
Patient Information leaflet Patient Information leaflet Dutch 10-10-2023
Public Assessment Report Public Assessment Report Dutch 12-01-2018
Patient Information leaflet Patient Information leaflet Polish 10-10-2023
Public Assessment Report Public Assessment Report Polish 12-01-2018
Patient Information leaflet Patient Information leaflet Portuguese 10-10-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 10-10-2023
Public Assessment Report Public Assessment Report Portuguese 12-01-2018
Patient Information leaflet Patient Information leaflet Romanian 10-10-2023
Public Assessment Report Public Assessment Report Romanian 12-01-2018
Patient Information leaflet Patient Information leaflet Slovak 10-10-2023
Public Assessment Report Public Assessment Report Slovak 12-01-2018
Patient Information leaflet Patient Information leaflet Slovenian 10-10-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 10-10-2023
Public Assessment Report Public Assessment Report Slovenian 12-01-2018
Patient Information leaflet Patient Information leaflet Finnish 10-10-2023
Public Assessment Report Public Assessment Report Finnish 12-01-2018
Patient Information leaflet Patient Information leaflet Swedish 10-10-2023
Public Assessment Report Public Assessment Report Swedish 12-01-2018
Patient Information leaflet Patient Information leaflet Norwegian 10-10-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 10-10-2023
Patient Information leaflet Patient Information leaflet Icelandic 10-10-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 10-10-2023
Patient Information leaflet Patient Information leaflet Croatian 10-10-2023
Public Assessment Report Public Assessment Report Croatian 12-01-2018

View documents history